Sign up
Quantellect · Congress · Trade Detail
NYSE: BMYBristol-Myers Squibb Company
DemocratSenate

Patty Murray bought Bristol-Myers Squibb Company (NYSE: BMY)

Patty Murray (D-WA), a U.S. Senator, has disclosed 2 trades in Bristol-Myers Squibb Company (BMY) since 2017, 1 purchase and 1 sale, worth an estimated $16K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a purchase: Patty Murray bought $1,001 - $15,000 of Bristol-Myers Squibb Company (NYSE: BMY) on March 16, 2017. Since that trade, BMY is up +52.78% against the S&P 500 up +254.29%, an outperformance of -201.51%.

Across these filings, Patty Murray has been a balanced trader of BMY (a buy-to-sell ratio of 1.00). The most recent disclosed BMY transaction shown was dated June 15, 2017. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

BMY trades
2
Disclosed Vol
$16K
Buys
1
50%
Sells
1
50%
Buy / Sell
1.00
ratio
First → Last
2017

Patty Murray's BMY trades vs the price

BMY is up +52.78% since Patty Murray bought on March 16, 2017, versus +254.29% for the S&P 500.

Performance since this trade

Price change since trade
+52.78%
S&P 500 change since trade
+254.29%
Outperformance vs S&P 500
-201.51%

All Patty Murray BMY trades

TradedTypeSizeReturnEst. profit
June 15, 2017SELL$39.40+60.15%
March 16, 2017BUY$41.30+52.78%+$808

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Patty Murray & BMY trading FAQ

Is it legal for Patty Murray to trade Bristol-Myers Squibb Company (BMY) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Patty Murray buy BMY?

Patty Murray disclosed a purchase of $1,001 - $15,000 of Bristol-Myers Squibb Company (BMY) on March 16, 2017, according to public STOCK Act filings.

How has BMY performed since Patty Murray's trade?

Since Patty Murray bought BMY on March 16, 2017, the stock is up +52.78%, versus +254.29% for the S&P 500 over the same period, an outperformance of -201.51%.

How many times has Patty Murray traded BMY?

Patty Murray has disclosed 2 BMY trades since 2017 (1 purchase and 1 sale). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional BMY trades?

Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.

Patty Murray's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyPatty Murray's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.